European Journal of Clinical Pharmacology

, Volume 38, Issue 6, pp 617–619 | Cite as

Metamizole: reassessment of its therapeutic role

  • F. Arellano
  • J. A. Sacristán
Short Communications


The use of metamizole is controversial, as reflected in the very different national regulations affecting it. The striking disparities between policies for metamizole made us try to determine if there were reasons to ban, limit or liberalize its utilization.

After reviewing the literature, it was concluded that metamizole should not be withdrawn from the countries where its use is still relatively free. However, metamizole causes life-threatening adverse events that are usually unpredictable and can only be prevented by better prescribing habits, so it is suggested that its use as a first-line agent should be restricted to the treatment of the pain of acute colic and circumstances in which parenteral administration of a non-narcotic agent is mandatory.

Studies are needed to determine the role of second-line oral analgesics in terms of their overall toxicity and efficacy. In the meantime it is proposed that oral metamizole should be used only when other analgesics (e. g. paracetamol) have failed.

Key words

metamizole analgesics adverse drug reaction colic 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kiatboonsri P, Richter J (1988) Unethical trials of dipyrone in Thailand. Lancet II: 1491Google Scholar
  2. 2.
    Handpadungdhama A (1989) Trials of dipyrone in Thailand. Lancet I: 788Google Scholar
  3. 3.
    Sriwatanakul K (1989) Trials of dipyrone in Thailand. Lancet I: 788Google Scholar
  4. 4.
    Anonymous (1989) Dipyrone. A drug no one needs. Health Action International-Europe & BUKO Pharma-Campaign, AmsterdamGoogle Scholar
  5. 5.
    Moffatt J (1986) Dipyrone-containing analgesics. S A Med J 70: 331–333Google Scholar
  6. 6.
    Bakke OM, Wardell WM, Lasagna L (1984) Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of safety. Clin Pharmacol Ther 35: 559–567Google Scholar
  7. 7.
    Gomez-Jimenez J, Franco-Patino R, Chargoy-Vera J, Olivares-Sosa R (1980) Clinical efficacy of mild analgesics in pain following gynecological or dental surgery: report on multicentre studies. Br J Clin Pharmacol 10: 355S-358SGoogle Scholar
  8. 8.
    Florez J (1987) Análgesicos antitérmicos. Antirreumáticos no esteroideos. In: Flórez J, Armijo JA, Mediavilla A (eds) Farmacología Humana, Vol I. Eunsa, Pamplona, pp 242–264Google Scholar
  9. 9.
    Mehslich DR (1983) Review of the comparative analgesic efficacy of salicylates, acetaminophen and pyrazolones. Am J Med 75: 47–52Google Scholar
  10. 10.
    Gladtke E (1983) Use of antipyretic analgesics in the pediatric patient. Am J Med 75: 121–125Google Scholar
  11. 11.
    Patel CV, Koppikar MG, Patel MS, Parulkar GR, Pinto Pereira LM (1980) Management of pain after abdominal surgery: dipyrone compared with petidine. Br J Clin Pharmacol 10: 351S-354SGoogle Scholar
  12. 12.
    Brogden RN (1986) Pyrazolone derivatives. Drugs 32 [Suppl 4]: 60–70Google Scholar
  13. 13.
    Kewitz H (1986) Rare but serious risks associated with non-narcotic analgesics: clinical experience. Med Toxicol 1 [Suppl 1]: 86–92Google Scholar
  14. 14.
    Lloret J, Muñoz J, Monmany J, Puig X, Bonastre M, Brau J, Sola J, Domingo P, Jane F (1987) Treatment of renal colic with dipyrone. A double-blind comparison trial with hyoscine alone or combined with dipyrone. Curr Ther Res 42: 1119–1128Google Scholar
  15. 15.
    Miralles R, Cami J, Gutierrez J, Torne J, Garces JM, Badenas JM (1987) Diclofenac versus dipyrone in acute renal colic: a double-blind controlled trial. Eur J Clin Pharmacol 33: 527–528Google Scholar
  16. 16.
    Anderson JA, Adkinson NR Jr (1987) Allergic reactions to drugs and biologic agents. JAMA 258: 2891–2899Google Scholar
  17. 17.
    Arndt KA, Hick H (1976) Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program. JAMA 235: 918–922Google Scholar
  18. 18.
    Levy M, Lipsitz M, Eliakim M (1979) Hospital admissions due to adverse drug reactions. Am J Med Sci 277: 49–56Google Scholar
  19. 19.
    Italian Group of Intensive Care Evaluation (1987) Epidemiology of adverse drug reactions in intensive care units. Eur J Clin Pharmacol 31: 507–512Google Scholar
  20. 20.
    The International Agranulocytosis and Aplastic Anemia Study Group (1986) Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. JAMA 256: 1749–1757Google Scholar
  21. 21.
    Fosseus CG, Straughan H (1983) Sudden death due to intravenous avapyrazone and dipyrone. S A Med J 64: 81Google Scholar
  22. 22.
    Arellano F, Soto J, Antepara I, Terrones J, Candina R, Perez I, De Cos MA (1990) Epidermolisis necrótica tóxica por metamizol. A propósito de un caso. Rev Clin Esp (in press)Google Scholar
  23. 23.
    Rummel W (1987) Metamizol: Kommentar zu Berichten über lebensbedrohliche Kreislauferkrankungen. Dtsch Ärzteblatt 84: B2408-B2412Google Scholar
  24. 24.
    Laporte J-R, Carne X (1987) Blood dyscrasias and the relative safety of non-narcotic analgesics. Lancet I: 809Google Scholar
  25. 25.
    Fowler PD (1987) Aspirin, paracetamol and non-steroidal anti-inflammatory drugs. A comparative review of side effects. Med Toxicol 2: 338–366Google Scholar
  26. 26.
    Duthie DJR, Nimmo WS (1987) Adverse effects of opioid analygesic drugs. Br J Anaesth 59: 61–77Google Scholar
  27. 27.
    Marks A, Abramson N (1980) Pentazocine and agranulocytosis. Ann Intern Med 92: 433Google Scholar
  28. 28.
    Sheehan M, Hyland RH, Norman C (1985) Pentazocine-induced agranulocytosis. Canad med Assoc J 132: 40Google Scholar
  29. 29.
    Hunter JAA, Davison AM (1973) Toxic epidermal necrolysis associated with pentazocin therapy and severe reversible renal failure. Br J Dermatol 88: 287–289Google Scholar
  30. 30.
    Paeile C, Gallardo F (1974) Analgesic activity of pentazocine and dipyrone in ambulatory oral patients. J Oral Surg 32: 191–194Google Scholar
  31. 31.
    Daftary SN, Mehta AC, Nanavati M (1980) A controlled comparation of dipyrone and paracetamol in post-episiotomy pain. Curr Med Res 6: 614–618Google Scholar
  32. 32.
    Mukherjee S, Sood S (1980) A controlled evaluation of orally administered aspirin, dipyrone and placebo in patients with post-operative pain. Curr Med Res 6: 619–623Google Scholar
  33. 33.
    Lehtonen T, Kellokumpu I, Permi J, Sarsila O (1983) Intravenous indomethacin in the treatment of ureteric colic. Ann Clin Res 15: 197–199Google Scholar
  34. 34.
    Comeri C, Radice GP, Duvia R, Manganini V, Monza G (1984) Efficacy and safety of non steroidal anti-inflammatory drugs in ureteral colic. A double-blind controlled trial (Abstract no 71) Urol Res 12: 45Google Scholar
  35. 35.
    Niinikoski J, Nelimarkka O, Pekkola P (1984) Intravenous indomethacin in biliary pain. Ann Chir Gynaecol 73: 69–72Google Scholar
  36. 36.
    Bentley KC, Head TW (1987) The additive analgesic efficacy of acetaminophen, 1000 mg and codeine, 60 mg, in dental pain. Clin Pharmacol Ther 42: 634–640Google Scholar
  37. 37.
    Barroso MH, Carranza JAU, Garcia JLG, Rodriguez LG (1982) Evaluación doble ciego de la eficacia analgésica y tolerancia de zomepirac sódico y dipirona, a dosis única en dolor postoperatorio. Invest Med Intern 9: 164–170Google Scholar
  38. 38.
    Mehta S (1967) Comparation of pethidine with sodium phenylalmethylpyrazolonemethylaminomethanesulphonate (Novalgin) and with a placebo in postoperative pain. Ind J Anaesth 232–237Google Scholar
  39. 39.
    Lal A, Pandey K, Chandra P, Pande SB (1973) Dipyrone for treatment of post-operative pain. Anesthesiol 28: 43–47Google Scholar
  40. 40.
    Rejman F (1984) Intravenous indomethacin in biliary pain: a clinical investigation with metamizole as the control. IRCS Med Sci 12: 399–400Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • F. Arellano
    • 1
    • 2
  • J. A. Sacristán
    • 1
  1. 1.Clinical Pharmacology ServiceHospital Marqués de ValdecillaSantanderSpain
  2. 2.Sandoz Pharma AGDrug Monitoring CentreBaselSwitzerland

Personalised recommendations